公开(公告)号：US12269898B2

公开(公告)日：2025-04-08

申请号：US16753216

申请日：2018-10-03

Applicant: AMGEN INC.

Inventor： Kenneth Walker

IPC: C07K19/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/47 ,  C07K16/28 ,  C07K16/00 ,  C12N15/63

Abstract: The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.

公开(公告)号：US09862752B2

公开(公告)日：2018-01-09

申请号：US14908459

申请日：2014-07-31

Applicant: Amgen Inc.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Z. Sheng ,  Agnes Eva Hamburger ,  Murielle Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Marissa Mock ,  Kenneth Walker

IPC: C07K14/00 ,  C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.